182 related articles for article (PubMed ID: 35637376)
1. Filgotinib: A Clinical Pharmacology Review.
Namour F; Anderson K; Nelson C; Tasset C
Clin Pharmacokinet; 2022 Jun; 61(6):819-832. PubMed ID: 35637376
[TBL] [Abstract][Full Text] [Related]
2. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Namour F; Fagard L; Van der Aa A; Harrison P; Xin Y; Tasset C
Br J Clin Pharmacol; 2018 Dec; 84(12):2779-2789. PubMed ID: 30088677
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
4. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
6. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
[TBL] [Abstract][Full Text] [Related]
7. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
[TBL] [Abstract][Full Text] [Related]
8. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.
Hsueh CH; Anderson K; Shen G; Yun C; Qin A; Othman AA
Clin Transl Sci; 2022 Feb; 15(2):361-370. PubMed ID: 34498807
[TBL] [Abstract][Full Text] [Related]
10. Filgotinib in rheumatoid arthritis.
Westhovens R
Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
[TBL] [Abstract][Full Text] [Related]
11. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
[TBL] [Abstract][Full Text] [Related]
12. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
13. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
14. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Kim ES; Keam SJ
Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
[TBL] [Abstract][Full Text] [Related]
15. MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.
Hellstrom WJG; Dolhain RJEM; Ritter TE; Watkins TR; Arterburn SJ; Dekkers G; Gillen A; Tonussi C; Gilles L; Oortwijn A; Van Beneden K; de Vries DE; Sikka SC; Vanderschueren D; Reinisch W
Adv Ther; 2022 Jul; 39(7):3403-3422. PubMed ID: 35614292
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
Anderson K; Nelson CH; Gong Q; Alani M; Tarnowski T; Othman AA
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):235-245. PubMed ID: 34468080
[TBL] [Abstract][Full Text] [Related]
17. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
[TBL] [Abstract][Full Text] [Related]
18. Filgotinib: First Approval.
Dhillon S; Keam SJ
Drugs; 2020 Dec; 80(18):1987-1997. PubMed ID: 33237566
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Graefe-Mody U; Retlich S; Friedrich C
Clin Pharmacokinet; 2012 Jul; 51(7):411-27. PubMed ID: 22568694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
